Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
Featured Posts
Today, a diagnosis of Pompe disease ties people to twice-monthly infusions of enzyme replacement therapy. Astellas is trying to change that with AT845, a gene therapy that would serve as a one-time treatment for patients with LOPD.
With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
The sales forecast implies a “possible EPS net loss” this year compared to the huge profit its COVID vaccines drove during its peak.
“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren wrote to Kathi Vidal, director of the United States Patent and Trademark Office (PTO) in the letter sent on Wednesday
The company announced its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc.’s drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.
British drugmaker GSK’s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.
Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.
Amazon.com Inc. said on Wednesday it had completed its $3.5 billion takeover of primary care provider One Medical (ONEM.O), a day after a U.S. Federal Trade Commission (FTC) official announced that the agency would not challenge the deal.
PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.